Melding together genomics technology, disease patterns, immunology, and microbiology, physician-scientists at The Children’s Hospital of Philadelphia are finding new and individualized therapies for patients with very early onset inflammatory bowel disease.
A study published in the Journal of Clinical Endicronology & Metabolism shows a drug approved to treat Crohn’s disease and ulcerative colitis leads to “rapid improvements” in bone density and structure.